The place of combined drugs based on regulatory peptides in the treatment of prostate diseases

Abstract

Benign prostatic hyperplasia is the most common urological disease in men over 50 years of age. The decrease in the quality of life of patients with benign prostatic hyperplasia dictates the need to study the risk factors for the development of this disease, as well as to develop effective treatment strategies. The development of benign prostatic hyperplasia is characterized by proliferation of stromal and epithelial cells in the transitional zone of the organ that surrounds the urethra, which leads to compression of the urethra and the development of symptoms of the lower urinary tract. The drugs of first choice for the treatment of patients with prostatic hyperplasia are α1-adrenoblockers, among which the selective drug Tamsulosin is the most popular. According to the literature, the use of Tamsulosin is associated with the risk of developing a number of serious side effects, which can negatively affect the quality of life of patients and reduce their adherence to treatment. The article provides information about a combined drug containing bioregulatory peptides and tamsulosin in the form of suppositories, which helps to reduce the systemic effect of the drug and the development of undesirable side effects.